Integrative biological analysis for neuropsychopharmacology

Mark Emmett, Roger A. Kroes, Joseph R. Moskal, Charles A. Conrad, Waldemar Priebe, Fernanda Laezza, Anke Meyer-Baese, Carol L. Nilsson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Although advances in psychotherapy have been made in recent years, drug discovery for brain diseases such as schizophrenia and mood disorders has stagnated. The need for new biomarkers and validated therapeutic targets in the field of neuropsychopharmacology is widely unmet. The brain is the most complex part of human anatomy from the standpoint of number and types of cells, their interconnections, and circuitry. To better meet patient needs, improved methods to approach brain studies by understanding functional networks that interact with the genome are being developed. The integrated biological approaches - proteomics, transcriptomics, metabolomics, and glycomics - have a strong record in several areas of biomedicine, including neurochemistry and neuro-oncology. Published applications of an integrated approach to projects of neurological, psychiatric, and pharmacological natures are still few but show promise to provide deep biological knowledge derived from cells, animal models, and clinical materials. Future studes that yield insights based on integrated analyses promise to deliver new therapeutic targets and biomarkers for personalized medicine.

Original languageEnglish (US)
Pages (from-to)5-23
Number of pages19
JournalNeuropsychopharmacology
Volume39
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Biomarkers
Glycomics
Neurochemistry
Precision Medicine
Metabolomics
Brain
Brain Diseases
Drug Discovery
Mood Disorders
Psychotherapy
Proteomics
Psychiatry
Anatomy
Schizophrenia
Animal Models
Cell Count
Genome
Pharmacology
Therapeutics

Keywords

  • neuro-oncology
  • neurological disease
  • psychiatric disorder
  • systems biology

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Emmett, M., Kroes, R. A., Moskal, J. R., Conrad, C. A., Priebe, W., Laezza, F., ... Nilsson, C. L. (2014). Integrative biological analysis for neuropsychopharmacology. Neuropsychopharmacology, 39(1), 5-23. https://doi.org/10.1038/npp.2013.156

Integrative biological analysis for neuropsychopharmacology. / Emmett, Mark; Kroes, Roger A.; Moskal, Joseph R.; Conrad, Charles A.; Priebe, Waldemar; Laezza, Fernanda; Meyer-Baese, Anke; Nilsson, Carol L.

In: Neuropsychopharmacology, Vol. 39, No. 1, 01.2014, p. 5-23.

Research output: Contribution to journalArticle

Emmett, M, Kroes, RA, Moskal, JR, Conrad, CA, Priebe, W, Laezza, F, Meyer-Baese, A & Nilsson, CL 2014, 'Integrative biological analysis for neuropsychopharmacology', Neuropsychopharmacology, vol. 39, no. 1, pp. 5-23. https://doi.org/10.1038/npp.2013.156
Emmett, Mark ; Kroes, Roger A. ; Moskal, Joseph R. ; Conrad, Charles A. ; Priebe, Waldemar ; Laezza, Fernanda ; Meyer-Baese, Anke ; Nilsson, Carol L. / Integrative biological analysis for neuropsychopharmacology. In: Neuropsychopharmacology. 2014 ; Vol. 39, No. 1. pp. 5-23.
@article{e2830c368262495bb8a85ceb1d28e214,
title = "Integrative biological analysis for neuropsychopharmacology",
abstract = "Although advances in psychotherapy have been made in recent years, drug discovery for brain diseases such as schizophrenia and mood disorders has stagnated. The need for new biomarkers and validated therapeutic targets in the field of neuropsychopharmacology is widely unmet. The brain is the most complex part of human anatomy from the standpoint of number and types of cells, their interconnections, and circuitry. To better meet patient needs, improved methods to approach brain studies by understanding functional networks that interact with the genome are being developed. The integrated biological approaches - proteomics, transcriptomics, metabolomics, and glycomics - have a strong record in several areas of biomedicine, including neurochemistry and neuro-oncology. Published applications of an integrated approach to projects of neurological, psychiatric, and pharmacological natures are still few but show promise to provide deep biological knowledge derived from cells, animal models, and clinical materials. Future studes that yield insights based on integrated analyses promise to deliver new therapeutic targets and biomarkers for personalized medicine.",
keywords = "neuro-oncology, neurological disease, psychiatric disorder, systems biology",
author = "Mark Emmett and Kroes, {Roger A.} and Moskal, {Joseph R.} and Conrad, {Charles A.} and Waldemar Priebe and Fernanda Laezza and Anke Meyer-Baese and Nilsson, {Carol L.}",
year = "2014",
month = "1",
doi = "10.1038/npp.2013.156",
language = "English (US)",
volume = "39",
pages = "5--23",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Integrative biological analysis for neuropsychopharmacology

AU - Emmett, Mark

AU - Kroes, Roger A.

AU - Moskal, Joseph R.

AU - Conrad, Charles A.

AU - Priebe, Waldemar

AU - Laezza, Fernanda

AU - Meyer-Baese, Anke

AU - Nilsson, Carol L.

PY - 2014/1

Y1 - 2014/1

N2 - Although advances in psychotherapy have been made in recent years, drug discovery for brain diseases such as schizophrenia and mood disorders has stagnated. The need for new biomarkers and validated therapeutic targets in the field of neuropsychopharmacology is widely unmet. The brain is the most complex part of human anatomy from the standpoint of number and types of cells, their interconnections, and circuitry. To better meet patient needs, improved methods to approach brain studies by understanding functional networks that interact with the genome are being developed. The integrated biological approaches - proteomics, transcriptomics, metabolomics, and glycomics - have a strong record in several areas of biomedicine, including neurochemistry and neuro-oncology. Published applications of an integrated approach to projects of neurological, psychiatric, and pharmacological natures are still few but show promise to provide deep biological knowledge derived from cells, animal models, and clinical materials. Future studes that yield insights based on integrated analyses promise to deliver new therapeutic targets and biomarkers for personalized medicine.

AB - Although advances in psychotherapy have been made in recent years, drug discovery for brain diseases such as schizophrenia and mood disorders has stagnated. The need for new biomarkers and validated therapeutic targets in the field of neuropsychopharmacology is widely unmet. The brain is the most complex part of human anatomy from the standpoint of number and types of cells, their interconnections, and circuitry. To better meet patient needs, improved methods to approach brain studies by understanding functional networks that interact with the genome are being developed. The integrated biological approaches - proteomics, transcriptomics, metabolomics, and glycomics - have a strong record in several areas of biomedicine, including neurochemistry and neuro-oncology. Published applications of an integrated approach to projects of neurological, psychiatric, and pharmacological natures are still few but show promise to provide deep biological knowledge derived from cells, animal models, and clinical materials. Future studes that yield insights based on integrated analyses promise to deliver new therapeutic targets and biomarkers for personalized medicine.

KW - neuro-oncology

KW - neurological disease

KW - psychiatric disorder

KW - systems biology

UR - http://www.scopus.com/inward/record.url?scp=84890501825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890501825&partnerID=8YFLogxK

U2 - 10.1038/npp.2013.156

DO - 10.1038/npp.2013.156

M3 - Article

VL - 39

SP - 5

EP - 23

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -